Outlook Therapeutics Sets U.S. Wholesale Price for LYTENAVA™ at $485 Per Vial

Outlook Therapeutics, Inc. has established the wholesale acquisition cost (WAC) for its product, LYTENAVA™, in the United States. This pricing announcement is a significant commercial milestone for the company.

Key Details

• Product: LYTENAVA™
• Price: $485 per vial (Wholesale Acquisition Cost)
• Market: United States
• Date of Event: September 16, 2026